Antimicrobial agents and chemotherapy · 2011
Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Jien-Wei, Ko Wen-Chien, Huang Cheng-Hua, Liao Chun-Hsing, Lu Chin-Te, Chuang Yin-Ching, Tsao Shih-Ming, Chen Yao-Shen, Liu Yung-Ching, Chen Wei-Yu, Jang Tsrang-Neng, Lin Hsiu-Chen, Chen Chih-Ming, Shi Zhi-Yuan, Pan Sung-Ching, Yang Jia-Ling, Kung Hsiang-Chi, Liu Chun-Eng, Cheng Yu-Jen, Chen Yen-Hsu, Lu Po-Liang, Sun Wu, Wang Lih-Shinn, Yu Kwok-Woon, Chiang Ping-Cherng, Lee Ming-Hsun, Lee Chun-Ming, Hsu Gwo-Jong, Hsueh Po-Ren
Аннотация
The Tigecycline In Vitro Surveillance in Taiwan (TIST) study, initiated in 2006, is a nationwide surveillance program designed to longitudinally monitor the in vitro activity of tigecycline against commonly encountered drug-resistant bacteria. This study compared the in vitro activity of tigecycline against 3,014 isolates of clinically important drug-resistant bacteria using the standard broth microdilution and disk diffusion methods. Species studied included methicillin-resistant Staphylococcus aureus (MRSA; n = 759), vancomycin-resistant Enterococcus faecium (VRE; n = 191), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (n = 602), ESBL-producing Klebsiella pneumoniae (n = 736), and Acinetobacter baumannii (n = 726) that had been collected from patients treated between 2008 and 2010 at 20 hospitals in Taiwan. MICs and inhibition zone diameters were interpreted according to the currently recommended U.S. Food and Drug Administration (FDA) criteria and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The MIC(90) values of tigecycline against MRSA, VRE, ESBL-producing E. coli, ESBL-producing K. pneumoniae, and A. baumannii were 0.5, 0.125, 0.5, 2, and 8 μg/ml, respectively. The total error rates between the two methods using the FDA criteria were high: 38.4% for ESBL-producing K. pneumoniae and 33.8% for A. baumannii. Using the EUCAST criteria, the total error rate was also high (54.6%) for A. baumannii isolates. The total error rates between these two methods were <5% for MRSA, VRE, and ESBL-producing E. coli. For routine susceptibility testing of ESBL-producing K. pneumoniae and A. baumannii against tigecycline, the broth microdilution method should be used because of the poor correlation of results between these two methods.
Предметные рубрики MeSH
Acinetobacter baumanniiAnti-Bacterial AgentsCarbapenemsDrug Resistance, BacterialEnterococcus faeciumEscherichia coliGram-Negative BacteriaGram-Positive BacteriaHumansKlebsiella pneumoniaeLongitudinal StudiesMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsMinocyclineTaiwanTigecyclineVancomycinbeta-Lactamases